TYME-88-PANC Phase II study showed patients being treated with SM-88, who achieved at least an 80% reduction in circulating tumor cell burden, demonstrated a 60% decrease in risk of death
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”